These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29121104)

  • 1. Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
    Xiao WJ; Zhu Y; Dai B; Ye DW
    PLoS One; 2017; 12(11):e0187887. PubMed ID: 29121104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer.
    Xiao WJ; Zhu Y; Zhu Y; Dai B; Ye DW
    World J Urol; 2018 May; 36(5):769-774. PubMed ID: 29372356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
    Han M; Walsh PC; Partin AW; Rodriguez R
    J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
    Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
    Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy.
    Iyer RV; Hanlon AL; Pinover WH; Hanks GE
    Cancer; 1999 Apr; 85(8):1816-21. PubMed ID: 10223577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
    Smitt MC; Heltzel M
    Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.
    Choi SY; Chi BH; Lim B; Kyung YS; You D; Jeong IG; Song C; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):537-543. PubMed ID: 31915914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
    Dess RT; Suresh K; Zelefsky MJ; Freedland SJ; Mahal BA; Cooperberg MR; Davis BJ; Horwitz EM; Terris MK; Amling CL; Aronson WJ; Kane CJ; Jackson WC; Hearn JWD; Deville C; DeWeese TL; Greco S; McNutt TR; Song DY; Sun Y; Mehra R; Kaffenberger SD; Morgan TM; Nguyen PL; Feng FY; Sharma V; Tran PT; Stish BJ; Pisansky TM; Zaorsky NG; Moraes FY; Berlin A; Finelli A; Fossati N; Gandaglia G; Briganti A; Carroll PR; Karnes RJ; Kattan MW; Schipper MJ; Spratt DE
    JAMA Oncol; 2020 Dec; 6(12):1912-1920. PubMed ID: 33090219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
    Antunes HP; Parada B; Carvalho J; Eliseu M; Jarimba R; Oliveira R; Tavares-da-Silva E; Figueiredo A
    Arch Ital Urol Androl; 2018 Sep; 90(3):191-194. PubMed ID: 30362685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
    D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
    Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
    Bhindi B; Karnes RJ; Rangel LJ; Mason RJ; Gettman MT; Frank I; Tollefson MK; Lin DW; Thompson RH; Boorjian SA
    J Urol; 2017 Dec; 198(6):1286-1294. PubMed ID: 28669765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing patient selection for prostate monotherapy.
    Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy.
    May F; Hartung R; Breul J
    BJU Int; 2001 Nov; 88(7):702-7. PubMed ID: 11890240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.